Verily Life Sciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Private Equity - II | Alive

Total Raised


Last Raised

$700M | 2 yrs ago

About Verily Life Sciences

Verily Life Sciences develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage disease. The company partners with leading life sciences, medical device and government organizations, using deep hardware, software, scientific, and healthcare expertise to enable faster development, meaningful advances, and deployment at scale.

Verily Life Sciences Headquarter Location

269 E Grand Ave

South San Francisco, California, 94080,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Verily Life Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Verily Life Sciences is included in 9 Expert Collections, including Conference Exhibitors.


Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare


Sleep Health & Wellness

800 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.


Medical Devices

12,317 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



1,750 items


Digital Health

13,072 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)



2,833 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

Verily Life Sciences Patents

Verily Life Sciences has filed 862 patents.

The 3 most popular patent topics include:

  • Ophthalmology
  • Sensors
  • Diabetes
patents chart

Application Date

Grant Date


Related Topics




Aircraft controls, Neurotrauma, Aircraft components, Aircraft wing design, Aircraft instruments


Application Date


Grant Date



Related Topics

Aircraft controls, Neurotrauma, Aircraft components, Aircraft wing design, Aircraft instruments



Latest Verily Life Sciences News

Dengue outbreak: Wolbachia mosquito project to be expanded to 1,400 more HDB blocks following 'promising' results

Jun 15, 2022

Dengue outbreak: Wolbachia mosquito project to be expanded to 1,400 more HDB blocks following 'promising' results A Red Dengue Alert banner is seen in Singapore. (File photo: CNA/Jeremy Long) SINGAPORE: A project to fight dengue by releasing specially bred mosquitoes will be expanded to eight more public housing locations, covering an additional 1,400 HDB blocks. The releases of male Wolbachia-Aedes mosquitoes in these new areas will start in July, Minister for Sustainability and the Environment Grace Fu announced on Wednesday (Jun 15). Speaking on the third and last day of the Asia Dengue Summit taking place in Singapore, Ms Fu said this will cover 300,000 homes, up from the current 160,000. Coverage will go up from 19 per cent to around 31 per cent of all HDB blocks. Project Wolbachia-Singapore involves the release of male mosquitoes infected with the Wolbachia bacteria. When these specially bred mosquitoes mate with urban female Aedes aegypti that do not carry Wolbachia, their resulting eggs do not hatch. Releases will also take place at some construction sites and non-HDB residential sites in dengue high-risk areas, Ms Fu added. "Besides reducing the population of Aedes aegypti mosquitoes in these areas, expansion will allow us to understand the impact of a large scale, multi-site deployment of Wolbachia technology on dengue cases," she said. The eight new locations are Bedok North, Bedok Reservoir, Yew Tee, Geylang, Hougang, Punggol, Sengkang and Woodlands, estates considered “high-risk areas”, the National Environment Agency (NEA) said separately in a media statement. The project currently covers around 1,800 HDB blocks across study sites in Yishun, Tampines, Choa Chu Kang and Bukit Batok towns, and within five square kilometres of landed estate at Marine Parade, comprising about 160,000 homes. To support the expansion, NEA will increase the number of male Wolbachia-Aedes mosquitoes produced every week from the current 2 million to 5 million by the end of the year, through a collaboration with partners Orinno Technology, Verily Life Sciences and the National Robotics Programme. In just six months, the number of dengue cases this year (14,000) has already exceeded the total for the whole of 2021, when 5,258 were reported, said NEA. INTERRUPTING ACTIVE DENGUE CLUSTERS The new sites for the Wolbachia project were chosen based on: Historical dengue risk level, Aedes aegypti population, the size and landscape of the area, and NEA's capacity for producing and releasing male Wolbachia-Aedes mosquitoes. Besides suppressing the urban populations of the Aedes aegypti mosquito in these sites, data collected will also help to determine the impact of the technology on dengue cases and clusters, NEA said. The Wolbachia technology will complement existing community efforts and vector control operations to reduce the dengue vector in Singapore, NEA said. The tool has been shown to be useful for reducing the risk of dengue transmission in a local area, typically taking at least three to four months before there is a significant reduction of Aedes aegypti population. Related:

Verily Life Sciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Verily Life Sciences Rank

  • When was Verily Life Sciences founded?

    Verily Life Sciences was founded in 2015.

  • Where is Verily Life Sciences's headquarters?

    Verily Life Sciences's headquarters is located at 269 E Grand Ave, South San Francisco.

  • What is Verily Life Sciences's latest funding round?

    Verily Life Sciences's latest funding round is Private Equity - II.

  • How much did Verily Life Sciences raise?

    Verily Life Sciences raised a total of $2.5B.

  • Who are the investors of Verily Life Sciences?

    Investors of Verily Life Sciences include Temasek, Silver Lake, Alphabet, Ontario Teachers' Pension Plan and X - The Moonshot Factory.

  • Who are Verily Life Sciences's competitors?

    Competitors of Verily Life Sciences include Digital Diagnostics and 7 more.

You May Also Like

Ada Health

Ada is a global health company founded by doctors, scientists, and industry pioneers to create new possibilities for personal health. Ada’s core system connects medical knowledge with AI to help people actively manage their health and medical professionals to deliver effective care. Ada collaborates with health systems and global non-profit organizations.


Epic specializes in the development of software for healthcare organizations.

Helix Logo

Helix connects people with the most fundamental aspect of what makes them unique: their own DNA. The company empowers consumers to discover and explore their own genomes through insights provided by its ecosystem of content partners.

Biofourmis Logo

Biofourmis discovers, develops, and delivers clinically-validated, software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology for pharmaceutical companies to demonstrate value, and cost-effective solutions for payers. Biofourmis has built Biovitals, a personalized, AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD, and chronic pain. The company was founded in 2015 and is based in Boston, Massachusetts.


Ezra provides early cancer detection for everyone by combining advanced medical imaging technology and Artificial Intelligence.


CALC Asia provides users in the insurance industry with an intelligent butler service system - aiFin. Through aiFin platform, users can instantly view and manage data, transaction content, submit and reply to inquiries, set reminders, and commission settlement details.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.